Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways

Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways

Background: The EGFR pathway is involved in intrinsic and acquired resistance to a wide variety of targeted therapies in cancer. Vaccination represents an alternative to the administration of anti-EGFR monoclonal antibodies, such as cetuximab or panitumumab. Here, we tested if anti-EGF antibodies ge...

Full description

Bibliographic Details
Main Authors: Silvia García-Roman, Mónica Garzón-Ibáñez, Jordi Bertrán-Alamillo, Núria Jordana-Ariza, Ana Giménez-Capitán, Beatriz García-Peláez, Marta Vives-Usano, Jordi Codony-Servat, Erik d'Hondt, Rafael Rosell, Miguel Ángel Molina-Vila
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Translational Oncology
Subjects:
EGF
Vaccine
Inhibitors
Akt
ERK
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523324000044

Internet

http://www.sciencedirect.com/science/article/pii/S1936523324000044

Similar Items